Operating-room polidocanol sclerotherapy for HHT-related epistaxis
European Archives of Oto-Rhino-Laryngology · 31.10.2026
DOI: 10.1007/s00405-026-10780-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 31.10.2026. Verfasst von Germán Martín-Viguer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Hereditary haemorrhagic telangiectasia (HHT) is frequently associated with recurrent epistaxis, causing morbidity and impaired quality of life. Data on operating room-based endonasal polidocanol sclerotherapy remain limited. This study aimed to assess the effectiveness, safety, patient acceptance, and procedural feasibility of this approach for HHT-related epistaxis.
Methods
A retrospective observational study was conducted in a tertiary referral centre including 20 adults with HHT treated with endonasal polidocanol sclerotherapy between March 2022 and December 2025. Clinical variables, visceral arteriovenous malformation (AVM) involvement, procedure-related variables, complications, and patient-reported outcomes were analysed.
Results
A total of 59 procedures were performed. Mean weekly epistaxis frequency decreased from 8.3 to 2.35 episodes per week ( p < 0.001), with a mean relative reduction of 68.1% and an effect size of 1.27. Seventeen patients (85%) met responder criteria, defined as a reduction of at least 50% in weekly epistaxis frequency compared with baseline. Fourteen patients (70%) presented visceral AVM involvement, and 35% had high-burden disease. Severe epistaxis episodes requiring hospital-based care showed a non-significant numerical decrease. Two patients (10%) experienced complications, one requiring hospital admission. Nineteen patients (95%) reported willingness to undergo the procedure again.
Conclusion
Operating room endonasal polidocanol sclerotherapy was associated with clinically meaningful reduction in epistaxis burden, high patient acceptance, and a favourable safety profile. This approach may represent a valuable option for selected patients with recurrent HHT-related epistaxis requiring structured management beyond an office-based setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. almanzo@alumni.uv.es.
- Department of Surgery, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain. almanzo@alumni.uv.es.
- Department of Surgery, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.
Zitieren
APA
Martín-Viguer, G., Almanzo, S., Mas-Sabater, J., Mosquera-Lloreda, N., Armengot-Carceller, M., & García-Piñero, A. (2026). Operating-room polidocanol sclerotherapy for HHT-related epistaxis. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10780-1
Vancouver
Martín-Viguer G, Almanzo S, Mas-Sabater J, Mosquera-Lloreda N, Armengot-Carceller M, García-Piñero A. Operating-room polidocanol sclerotherapy for HHT-related epistaxis. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-026-10780-1
BibTeX
@article{MartnViguer2026,
author = {Martín-Viguer, Germán and Almanzo, Santiago and Mas-Sabater, Javier and Mosquera-Lloreda, Nezly and Armengot-Carceller, Miguel and García-Piñero, Alfonso},
title = {Operating-room polidocanol sclerotherapy for HHT-related epistaxis},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2026},
doi = {10.1007/s00405-026-10780-1}
}
EUVIMED